XXIII Encuentro de Cooperación Farma-Biotech

28 de noviembre de 2023

NAX035: A Berberine derivative for the treatment of cancer



Dr. Carme Plasencia








farmaindustria

Content

- 1. Company overview
- 2. The concept behind
- 3. Product
- a) Target Indication
- b) Innovative mechanisms of action
- c) Current status of development
- d) Pitfalls & Risks to be considered
- e) Differential features facing the market
- 4. Partnering Opportunities

> Privately-held drug development company mainly focused on Oncology > Developing a novel class of RNA-targeting drugs



- > Focusing on mRNA as therapeutic target
- Addressing targets with medical value oncogenic drivers whose overexpression are related to cancer progression and drug resistance
- Addressing poorly responsive tumors and unmet oncology medical needs

> A first candidate targeting TYMS-driven cancers advancing into Phase1/2 trial

> Further pipeline expansion into newer oncogenic targets

Well-balanced and highly experienced management team

Dr. Carmen Plasencia Co-founder & CEO

- MBA, Ph.D. Medicine, BSc Chemistry
- 26years experience on oncology drug development
- 2 patents, Over 15publication
- EU external expert, Start-up mentor, BA



Mr. Narcís Clavell Co-founder, CFO & Chairman Board

- MBA (IESE), Telecommunications Engineer.
- Private investor of several SMEs in Europe.
- 30-plus years experience in moving academic technologies to commercial enterprises

International Advisory Board

Oncology drug development

Dr. Paolo Lombardi Naxospharma, CEO

R&D VP Chemistry Menarini, Discovered Aromasin, for breast cancer

Dr. Cristina Geroni

Aesis Therapeutics, CEO 35+yr Oncology R&D Ex-Head Preclinical Nerviano.

Dr. Albert Abad

Medical Oncologist 35+ yr Oncologist MD, PhD. Head of the Digestive Unit Institut Oncològic Dr. Rosell

Financial & business strategy

Dr. Werner Wolff

Bioinnovation, CEO VP of R&D at Boehringer Mannheim Executive postictions TVM Capital

Dr. Nancy J Levy

Biohealth Management CEO CEO of Immunetics, together with different executive positions at Genzyme and Millennium.

✿ Ms. Orily Pratt

CEO Orily Pratt consultancy Marketing, branding & positioning +25 years experience in Marketing in top global corporations

Key Support



RNA THERAPEUTICS: Substantial market & growth opportunities

- RNA therapies A solution for "non-yet drugged" targets not ammenable for therapeutic intervention
- RNA therapeutics Market is expected to reach \$1.2Bn (CAGR of 28,4%)
- Remarkable speed
 - mRNA vaccines have revolution the panorama
 - Recently approved mRNA therapeutics (2020) -RNA interference (siRNA, miRNA) and RNA antisense (ASO) are driving the market



Source: www.researchandmarkets.com; www.alliedmarketresearch.com


Oncology holds significant market share (40%) – next frontier growing market for mRNA therapeutics

SOLVING RNA THERAPEUTIC CHALLENGES

	RNA THERAPEUTICS			
	(RNA-binding small molecule)	ANTISENSE OLIGONUCLEOTIDES	RNAi (siRNA, shRNA, miRNA, mRNA)	
TARGET SPECIFICITY	✓	✓	\checkmark	
ALL TARGETS	\checkmark	\checkmark	\checkmark	
LOCALIZATION (Intracel/Extracel.)	~	\checkmark	\checkmark	
POTENCY	1	\checkmark	\checkmark	
BIOAVAILABILITY	\checkmark	×	×	
LACK OF IMMUNOGENICITY	✓	×	×	
STABILITY	\checkmark	×	×	
NO DELIVERY REQUIREMENT	\checkmark	×	×	
MANUFACTURE COST	✓	×	×	
ORAL POSOLOGY POTENTIAL	\checkmark	×	×	

Our approach

By harnessing new insights into mRNA structural domains, AROMICS aims to develop newly first-in-class molecules targeting translational control, with biological stability and appropriate pharmacokinetic properties, that selectively bind to relevant transcripts involved in cancer and silence nascent protein expression



SMALL MOLECULES TARGETING RNA _ A HOT TOPIC FOR PHARMA DEALS

Start up	Licensor	Indication	Date Deal	Terms (upfront + milestones)
Skyhawk Therapeutics	Celgene (BMS)	Autoimmune & metabolic diseases	26/06/2018	\$60M + Undisclosed milestones
Anima Biotech	Eli Lilly	Not disclosed	23/07/2019	\$30M + \$1.05B
Skyhawk Therapeutics	Biogen	Different indications including neurological	04/01/2019	\$74M + undisclosed milestones
Skyhawk Therapeutics	Celgene (BMS)	Autoimmune, oncology & immunoncology	12/11/2019	\$80M + undisclosed milestones
Skyhawk Therapeutics	Genentech	Cancer & neurodegenerative diseases	16/07/2019	Undisclosed upfront + \$2.0B
Skyhawk Therapeutics	Takeda	Neurodegenerative diseases	06/05/2019	Not disclosed
Skyhawk Therapeutics	Merck	Neurodegenerative diseases & cancer	12/05/2020	\$600M + milestones per program
Arrakis Therapeutics	Roche	Covering all Roche R&D areas	08/04/2020	\$190M + "several billion dollars"
Accent Therapeutic	AstraZeneca	Cancer & other diseases	04/06/2020	\$55M + \$1.1B
Skyhawk Therapeutics	Vertex	Not disclosed	22/12/2020	\$40M + \$2.2B
Ribometrix	Roche/Genentech	Not disclosed	06/01/2021	\$25M + \$1B
Rgenta Therapeutics	Lundbeck	Neurodegenerative diseases	01/08/2021	\$10M + \$100M
Arrakis Therapeutics	Janssen	Multiple therapeutic areas	01/01/2022	\$75 + "several billion dollars"
Remix Therapeutics	Janssen	Not disclosed	17/02/2022	\$45M + \$950M
Anima Biotech	Abbvie	Oncology	10/01/2023	\$42M + \$582M

AROMICS position in market – Advancing our molecules to up to Clinical setting

	SMALL MOLECULES TARGETING RNA	DISCOVERY	OPTIMIZATION	PRECLINICAL DATA	NON-CLINICAL PACKAGE	PRE-IND	CLINICAL
	SKYHAWK THERAPEUTICS						
	ARRAKIS THERAPEUTICS						
	ANIMA BIOTECH						
****	EXPANSION THERAPEUTICS						
	ACCENT THERAPEUTICS						
	RIBOMETRIX						
	STORM THERAPEUTICS						
Š	AROMICS						


- > RNA targeting small molecules market ~ \$8.3 Bn in 2030
- > Two first FDA approved drugs (Duchenne and Spinal muscular atrophy). None in oncology

OUR TECHNOLOGY _ WHAT MAKES OUR ASSETS UNIQUE

An integrative technology platform combining best of cutting-edge anticancer strategies







Small molecule targeting specific regulatory elements in mRNA of cancer targets Chemical libraries of bioactive ligands affecting cancer cell metabolism Expert knowledge to improve lead compound while looking for taking profit of cancer cell vulnerabilities

To create more effective Cancer Therapies for hard-to-treat oncology malignancies

PIPELINE: A first lead advancing to clinical development, cornerstone of business growth

	COMPOUND	MOLECULE TYPE	MECHANISM OF ACTION	INDICATION	IN VITRO PoC	IN VIVO Poc	PRECLINIC	CLINIC	
			Translation inhibition	Malignant Mesothelioma					
				Small cell lung cancerr (SCLC)					
				Non-small cell lung cancer (NSCLC)					
	NAX035	Small molecule		Ovarian Cancer					
				Leukemia CML /Myelodisplasia					
				Colorectal cancer					NAXPLATFORM
				Rabdhiosarcoma cancer					GRANTED PATENTS
			Translation	Breast cancer HER2+					03, EO AND JAFAN
	NAX analogues	Small molecule /		Colorectal cancer					
	unurogues			Pancreatic cancer					
	TNL	Gene therapy	Trasncription inhibition	Different malignancies					


NAX035: Product Development

• Strategic case indication PoC – Malignant mesothelioma





Scalability potential in other indications

The medical need: Malignant mesothelioma - among the top ten occupational cancers of the world



Despite intensive efforts, no good solution yet in market





Non-responders – No therapeutic option Novel solutions are required

PFS: Progression-free survival; OS: overall survival

Value proposition - binding to mRNA of a validated target in mesothelioma



De-risking development strategy


- Clinically validated target >
- Rank among top 30 genes cancer cells needs for survive and growth (gene fitness score)
- > Involved in DNA replication and repair and Epithelial to mesenchymal (EMT) transition & metastasis



Predictive & prognostic value

- > Prognostic & predictive marker in solid & heamatological tumors
- > TS overexpression correlates with poor prognosis and drug resistance
- > Antimetabolites & antifolates inhibiting TS protein are first-line cancer treatments

TS mRNA as therapeutic target




- Identified a target element across TS mRNA
- NAX035 compete with TS for binding to its cognate mRNA
- Abolish aberrant protein expression
- **Post-transcription event** sustained silencing of TS protein without altering TS-mRNA expression level
- Avoids primary or secondary-drug resistance due to TS protein overexpression

Dr. Raphael Buen



Iniversität HARVARD WOMPN'S HOSPITA


NAX035- a highly valuable anticancer asset



Ready to move to Phase I/II clinical trials




CURRENT DEVELOPMENT STATUS _ PHASE 1/2 CLINICAL DEVELOPMENT



forward into randomized Phase 2 trial

Mesothelioma _ A Market opportunity ?

Estimated world new cases from 2020 up to 2040




Cancer Tomorrow | IARC - All Rights Reserved 2023 - Data version: 2020

- Pemetrexed (standard of care) patent loss
- Generics of Pemetrexed same anticipated problems
- >75% patients PFS in 6-7 months (even Immunoth.)
- **NEW therapeutic approaches** required for poor responders




Market value \$636 Mn by 2025

Targeting TS-mRNA, is highly relevant strategy in different tumors




TS is an essential TS in lung adenocarcinoma (ADC) NSCLC gene and squamous cell carcinoma (SCC) Siddiqui A et al. Br J Cancer (2021) 124, 281–289




TS prognostic and predictive marker after Hepatocarcinoma resection

Donner DB, et al. PLoS One. 2019;14(7):e0219469.



TS maintains the de-differentiated state of triple negative breast cancers Siddigui A et al (2019) Cell Death Differ 26, 2223–2236




TS predictive marker in pancreatic cancers. High levels prompts metastatic progression.

Lee et al, 2014, Int. J. Cancer: 135, 128–137 Kang M et al. Cancer Lett. 2018, 419:40-52

Overexpression of TYMS induced the development of tumors after a long latency, suggesting that aberrantly elevated TYMS cooperates with other cancer gene mutations to drive the neoplastic process

Potential market for additional indications



What we offer in mesothelioma + further TYMS_driven tumors

Compared to	Main market attributes
Mesothelioma treatment	 New Mechanism of action & patient selection Enlarged market – combination with chemo/immunotherapy Safety improvement Targeting sensitive & refractory tumors, irrespective of histology
Classical TS inhibitors	 > First-in-class TS Translational regulator (silencing TS not inhibiting) > Engaging different anticancer response > Interfering on canonical and non-canonical activities of TS > Efficacy regardless TYMS expression levels
Other RNA-targeting compounds	 > Target specific -Proved ability as RNA ligand > Appropriate Efficacy PK, safety and tox > Non-immunogenic, no delivery requirement, good stability > Robust manufacture > Oral potential

NO SIMILAR PRODUCT IN MARKET – ADDRESSING TYMS-DRIVEN TUMORS

XXIII Encuentro de Cooperación Farma-Biotech

Benefits of partnership With us

Strenghts of the compound	Benefit	Partner Benefit
Known target	First-in-class	De-risk clinical trial
Orphan indication	Lower n ^o patients & development costs	Market exclusivity
Clinical Trial	Additional TYMS-driven tumors	De-risk trial while scale-up
Regulatory challenges	Regular small molecule	Clear regulatory path
Financial requirements	Grant for phase 1 trial	Sharing development costs

RISK	Mitigation
Granted IP – composition of matter become old	 > IP strategy > Ensured FTO > Orphan drug designation pursued
Strategy to market	 Development to market guided by indication Precision medicine strategies Looking for optimal combinotherapies
Irruption of other agents in mesothelioma market	 Orphan designation sought Precision medicine strategies – selecting subset of patients with molecular characteristics

Pitfalls & RISKS

"Working on Innovative First-in-Class Therapies, Selectively Targeting RNA to Treat Cancer"

Contact information

Applied Research using Omic Sciences S.L. c/ Aribau 168 08036Barcelona SPAIN <u>www.aromics.es</u> <u>www.bermesproject.eu</u> <u>info@aromics.es</u>



* Aromics' developments have been partially supported by European Union, National, and Regional Public funding



